Cynata Therapeutics Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Cynata Therapeutics's earnings have been declining at an average annual rate of -16.2%, while the Biotechs industry saw earnings growing at 12.6% annually. Revenues have been declining at an average rate of 7.6% per year.
Información clave
-16.2%
Tasa de crecimiento de los beneficios
-3.5%
Tasa de crecimiento del BPA
| Crecimiento de la industria Biotechs | 9.6% |
| Tasa de crecimiento de los ingresos | -7.6% |
| Rentabilidad financiera | -135.0% |
| Margen neto | -420.8% |
| Última actualización de beneficios | 30 Jun 2024 |
Actualizaciones de resultados anteriores recientes
No hay actualizaciones
Recent updates
Here's Why We're Watching Cynata Therapeutics' (ASX:CYP) Cash Burn Situation
Sep 21
Will Cynata Therapeutics (ASX:CYP) Spend Its Cash Wisely?
May 29We're A Little Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn Rate
Feb 09We're Interested To See How Cynata Therapeutics (ASX:CYP) Uses Its Cash Hoard To Grow
Feb 02We Think Cynata Therapeutics (ASX:CYP) Can Easily Afford To Drive Business Growth
Sep 09Here's Why We're Not At All Concerned With Cynata Therapeutics' (ASX:CYP) Cash Burn Situation
May 26Here's Why We're Not Too Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn Situation
Dec 31We're Not Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn
Aug 11Desglose de ingresos y gastos
Cómo gana y gasta dinero Cynata Therapeutics. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 30 Jun 24 | 2 | -10 | 2 | 9 |
| 31 Mar 24 | 2 | -12 | 2 | 11 |
| 31 Dec 23 | 2 | -14 | 2 | 12 |
| 30 Sep 23 | 2 | -14 | 2 | 12 |
| 30 Jun 23 | 2 | -14 | 2 | 12 |
| 31 Mar 23 | 2 | -12 | 2 | 11 |
| 31 Dec 22 | 3 | -9 | 2 | 9 |
| 30 Sep 22 | 5 | -7 | 2 | 9 |
| 30 Jun 22 | 8 | -5 | 3 | 9 |
| 31 Mar 22 | 8 | -5 | 5 | 6 |
| 31 Dec 21 | 8 | -4 | 7 | 4 |
| 30 Sep 21 | 5 | -6 | 5 | 4 |
| 30 Jun 21 | 2 | -8 | 3 | 4 |
| 31 Mar 21 | 2 | -7 | 2 | 5 |
| 31 Dec 20 | 3 | -6 | 0 | 6 |
| 30 Sep 20 | 5 | -5 | 1 | 6 |
| 30 Jun 20 | 7 | -4 | 2 | 6 |
| 31 Mar 20 | 6 | -6 | 3 | 6 |
| 31 Dec 19 | 4 | -8 | 4 | 6 |
| 30 Sep 19 | 3 | -8 | 3 | 6 |
| 30 Jun 19 | 1 | -8 | 2 | 6 |
| 31 Mar 19 | 1 | -7 | 2 | 4 |
| 31 Dec 18 | 1 | -6 | 2 | 3 |
| 30 Sep 18 | 1 | -5 | 2 | 3 |
| 30 Jun 18 | 1 | -5 | 1 | 3 |
| 31 Mar 18 | 1 | -5 | 1 | 3 |
| 31 Dec 17 | 1 | -5 | 1 | 3 |
| 30 Sep 17 | 2 | -5 | 1 | 3 |
| 30 Jun 17 | 2 | -5 | 1 | 3 |
| 31 Mar 17 | 2 | -4 | 1 | 4 |
| 31 Dec 16 | 2 | -3 | 0 | 4 |
| 30 Sep 16 | 1 | -4 | 1 | 4 |
| 30 Jun 16 | 1 | -5 | 1 | 4 |
| 31 Mar 16 | 1 | -5 | 2 | 3 |
| 31 Dec 15 | 1 | -5 | 3 | 2 |
| 30 Sep 15 | 1 | -4 | 2 | 2 |
| 30 Jun 15 | 0 | -4 | 1 | 2 |
| 31 Mar 15 | 0 | -3 | 2 | 1 |
| 31 Dec 14 | 0 | -3 | 2 | 1 |
| 30 Sep 14 | 0 | -3 | 2 | 1 |
| 30 Jun 14 | 0 | -3 | 2 | 1 |
| 31 Mar 14 | 0 | -3 | 2 | 0 |
| 31 Dec 13 | 0 | -2 | 1 | 0 |
Ingresos de calidad: CYP is currently unprofitable.
Margen de beneficios creciente: CYP is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: CYP is unprofitable, and losses have increased over the past 5 years at a rate of 16.2% per year.
Acelerando crecimiento: Unable to compare CYP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: CYP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (2.5%).
Rentabilidad financiera
Alta ROE: CYP has a negative Return on Equity (-135.02%), as it is currently unprofitable.